C83.47 Immunoblastic (diffuse) non-Hodgkin's lymphoma, spleen

Name of the Condition

• Immunoblastic (diffuse) non-Hodgkin's lymphoma, spleen
• Also known as ICD-10 code C83.47

Summary

Immunoblastic (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of immunoblasts, a type of immature B-cell. It typically involves diffuse growth patterns in lymph nodes or other lymphoid tissues, with a tendency for rapid progression. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific subtype.

Causes

The exact cause of immunoblastic (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in B-cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT or MRI), and biopsy of affected tissue. Laboratory tests, including blood work and bone marrow aspiration, may also be performed to assess disease extent and rule out other conditions. Pathological analysis of biopsy samples is critical to confirm the diagnosis and subtype.

Treatment Options

Treatment depends on the stage, location, and patient factors. Options may include chemotherapy, immunotherapy, radiation therapy, or targeted therapies. Stem cell transplantation may be considered for eligible patients. Treatment plans are individualized and often involve a multidisciplinary team.

Prognosis and Follow-Up

Prognosis varies based on disease stage, patient age, and overall health. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance may be recommended to detect late effects or secondary malignancies.

Complications

Potential complications include infection due to immunosuppression, organ dysfunction from tumor burden, treatment-related toxicities, and transformation to a more aggressive lymphoma subtype.

Lifestyle & Prevention

Maintaining a healthy lifestyle, avoiding known carcinogens, and managing chronic infections may help reduce risk. Vaccinations and infection prevention are important for immunocompromised patients.

When to Seek Professional Help

Seek medical attention for persistent symptoms like unexplained weight loss, fever, or swollen lymph nodes. Prompt evaluation is critical if symptoms worsen or new concerning signs appear.

Tips for Medical Coders

Code C83.47 is specific to immunoblastic (diffuse) non-Hodgkin's lymphoma involving the spleen. Documentation should clearly specify the site (spleen) and histological subtype to support accurate coding. Ensure alignment with ICD-10-CM guidelines for site-specific lymphoma codes.